Metastasis to Breast from Extramammary Solid Tumors and Lymphomas: A 20-Year Population-Based Study

2021 ◽  
pp. 1-12
Author(s):  
Yihang Qi ◽  
Xiangyi Kong ◽  
Xiangyu Wang ◽  
Jie Zhai ◽  
Yi Fang ◽  
...  
2020 ◽  
Vol 8 (7) ◽  
pp. 482-482 ◽  
Author(s):  
Jin-Feng Huang ◽  
Jianfei Shen ◽  
Xiao Li ◽  
Ramesh Rengan ◽  
Nicola Silvestris ◽  
...  

2011 ◽  
Vol 58 (4) ◽  
pp. 561-565 ◽  
Author(s):  
Amos Hong Pheng Loh ◽  
LeLe Aung ◽  
Christina Ha ◽  
Ah-Moy Tan ◽  
Thuan Chong Quah ◽  
...  

2019 ◽  
Author(s):  
Jin-Feng Huang ◽  
Jianfei Shen ◽  
Xiao Li ◽  
Ramesh Rengan ◽  
Nicola Silvestris ◽  
...  

2013 ◽  
Vol 31 (30) ◽  
pp. 3807-3814 ◽  
Author(s):  
Chunkit Fung ◽  
Sophie D. Fossa ◽  
Michael T. Milano ◽  
Jan Oldenburg ◽  
Lois B. Travis

Purpose Increased risks of solid tumors after older radiotherapy strategies for testicular cancer (TC) are well established. Few population-based studies, however, focus on solid cancer risk among survivors of TC managed with nonradiotherapy approaches. We quantified the site-specific risk of solid cancers among testicular nonseminoma patients treated in the modern era of cisplatin-based chemotherapy, without radiotherapy. Patients and Methods Standardized incidence ratios (SIRs) for solid tumors were calculated for 12,691 patients with testicular nonseminoma reported to the population-based Surveillance, Epidemiology, and End Results program (1980 to 2008) and treated initially with either chemotherapy (n = 6,013) or surgery (n = 6,678) without radiotherapy. Patients accrued 116,073 person-years of follow-up. Results Two hundred ten second solid cancers were observed. No increased risk followed surgery alone (SIR, 0.93; 95% CI, 0.76 to 1.14; n = 99 solid cancers), whereas significantly increased 40% excesses (SIR, 1.43; 95% CI, 1.18 to 1.73; n = 111 solid cancers) occurred after chemotherapy. Increased risks of solid cancers after chemotherapy were observed in most follow-up periods (median latency, 12.5 years), including more than 20 years after treatment (SIR, 1.54; 95% CI, 0.96 to 2.33); significantly increased three- to seven-fold risks occurred for cancers of the kidney (SIR, 3.37; 95% CI, 1.79 to 5.77), thyroid (SIR, 4.40; 95% CI, 2.19 to 7.88), and soft tissue (SIR, 7.49; 95% CI, 3.59 to 13.78). Conclusion To our knowledge, this is the first large population-based series reporting significantly increased risks of solid cancers among patients with testicular nonseminoma treated in the modern era of cisplatin-based chemotherapy. Subsequent analytic studies should focus on the evaluation of dose-response relationships, types of solid cancers, latency patterns, and interactions with other possible factors, including genetic susceptibility.


2001 ◽  
Vol 120 (5) ◽  
pp. A628-A628
Author(s):  
E LOFTUSJR ◽  
C CROWSON ◽  
W SANDBORN ◽  
W TREAMINE ◽  
W OFALLON ◽  
...  

2005 ◽  
Vol 173 (4S) ◽  
pp. 73-73 ◽  
Author(s):  
Daniel A. Barocas ◽  
Farhang Rabbani ◽  
Douglas S. Scherr ◽  
E. Darracott Vaughan

Sign in / Sign up

Export Citation Format

Share Document